Concurrent EGFR and KRAS mutations in non-small cell lung cancer: Challenging the paradigm of linear targeted therapy. (2025). Journal of Current Biomedical Reports, 6(2), 45-46. https://doi.org/10.61882/jcbior.6.2.299